The purpose of the study is to evaluate the clinical efficacy and safety of etimicin on the treatment of bacterial infections
in respiratory and urinary tracts. 143 patients were involved in the prospective randomized-controlled and open clinical trial. There were two formulations of etimicin, i.e. etimicin in solution and etimicin in powder. In the randomized-controlled study 30 patients were treated with etimicin in solution or
netimicin,
respectively. In addition, in the open study there were 40 patients only treated with etimicin in solution. When etimicin in powder was used, 21 patients were treated with etimicin and 22 patients were treated with netimicin. Etimicin and netimicin were administered twice a day for 7-10 days, at a daily dose of 200 mg. The clinical efficacy rates of etimicin in solution and netimicin were both 90.0%, and the bacterial clearance rates were 86.2% and 80.0%, respectively. The adverse reactions were both 10.0% respectively. The clinical efficacy rate, bacterial clearance rate and adverse reactions rate in open clinical trial were 87.5%, 75.6% and 10.0%, respectively. The results of etimicin in powder were similar to those obtained from etimicin in solution. Etimicin sulfate is a new effective and safe antibiotics of aminoglycosides.